On Tuesday August 20th at 11 a.m. EST, OAHP is hosting a free webinar entitled Overview of Obesity sponsored by Novo Nordisk.

Overview of Obesity

Speaker: Nabeel Qureshi, PharmD, MPH, BCPS, Medical Liaison

August 20th, 2019 at 11 a.m. EST

Novo Nordisk, a global leader in diabetes care, has been committed to discovering and developing innovative medicines to help people with serious chronic conditions lead longer, healthier lives with fewer limitations.  We’re working toward a future where fewer people get diabetes, everyone is diagnosed, and all patients receive adequate treatment.

A third of adults in Ohio are obese, ranking the state eleventh in prevalence of obesity in the U.S.  Health plans are well positioned to address this public health challenge.  Doing so will require a comprehensive understanding of overweight and obesity.

Please join our webinar on August 20th for an overview of overweight and obesity, including but not limited to an examination of the multiple factors leading to overweight and obesity, the economic burden this presents, current guideline recommendations, and a discussion about what health plans can do to help stem this public health concern.

Session attendees will learn about:

  • The pathophysiology of obesity

  • Current clinical guideline recommendations for weight management, including diet, exercise, medications, and surgery

  • The economic burden of obesity

Register Now!  After registering, you will receive a confirmation email containing information about joining the meeting.

Please Note: This seminar is intended to be educational.  OAHP does not recommend any particular care management vendor.

On Tuesday September 24th at 2 p.m. EST, OAHP is hosting a free webinar entitled 2019/2020 Changes In Acute Treatment of Migraine sponsored by Allergan.

2019/2020 Changes In Acute Treatment of Migraine

Speaker: Colleen Smith, PharmD, Allergan National Accounts Scientific Director

September 24th, 2019 at 2 p.m. EST

Plain and simple, Allergan aims to be “Migraine, Inc” for the medical industry.  Botox for Chronic Migraine has been the foundational treatment for headache prophylaxis since its’ FDA-approval in 2010 and has multiple products in its’ pipeline for various conditions associated with migraines.  Allergan feels it is our responsibility to help insurers to not only understand Allergan’s products but to also understand all of the continued landscape changes that are occurring.

In late 2019 and early 2020, it is expected that there will be two new classes, encompassing three new products, approved to treat acute migraine symptoms.  This webinar is aimed to help the OAHP member participants understand each of these new treatments.

Please join our webinar on September 24th for the landscape and overview of 2019/2020 Changes In Acute Treatment of Migraine.

Session attendees will learn about: 

  • Burden of migraines on a health plan

  • Medical and financial impact of triptan insufficient responders

  • The need for new treatments specifically for triptan insufficient responders

  • The clinical profile of each new product coming to market



Meeting number: 719 222 630Meeting

password: YgpuNEw7


Call-in toll-free number: 1-866-279-9515

Conference Code: 497 765 6735

Please Note: This seminar is intended to be educational.  OAHP does not recommend any particular care management vendor.